8-K: Cerus Corporation Announces Strong 2024 Financial Results, Driven by Product Revenue Growth

Cerus Corporation reports a 15% increase in full-year 2024 product revenues and reiterates its 2025 product revenue guidance.

Summary

• Cerus Corporation announced its financial results for the full year and fourth quarter ended December 31, 2024.
• Full-year 2024 product revenue increased by 15% to $180.3 million, up from $156.4 million in the prior year.
• Fourth quarter product revenue increased by 9% to $50.8 million, compared to $46.8 million in the prior year period.
• The company achieved positive non-GAAP adjusted EBITDA of $5.7 million for 2024, compared to a loss of $10.7 million in 2023.
• Cerus generated positive operating cash flows for the fourth consecutive quarter, bringing year-to-date positive operating cash flows to $11.4 million.
• The company is reiterating its full-year 2025 product revenue guidance range of $194 million to $200 million, which includes $12 million to $15 million for INTERCEPT Fibrinogen Complex (IFC).

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and positive cash flow. The reiteration of 2025 revenue guidance further reinforces the positive sentiment.

Positives

• Product revenue increased by 15% for the full year 2024.
• IFC product revenue grew by 42% for the full year 2024.
• The company achieved positive non-GAAP adjusted EBITDA of $5.7 million for 2024.
• Operating cash flows improved by approximately $55 million year-over-year.
• The company is reiterating its full-year 2025 product revenue guidance of $194 million to $200 million.
• GAAP net loss attributable to Cerus Corporation improved by over 40% to $20.9 million from $37.5 million for the previous year.

Negatives

• Government contract revenue decreased by 31% for the full year 2024.
• Product gross margin for the fourth quarter of 2024 decreased to 53.9% compared to 55.5% for the prior year period.
• Net loss attributable to Cerus Corporation for the fourth quarter of 2024 was $2.5 million, compared to a net loss of $1.3 million for the fourth quarter of 2023.

Risks

• The company faces risks associated with the commercialization and market acceptance of the INTERCEPT Blood System.
• Macroeconomic developments, including the military conflict in Ukraine, could negatively impact business operations and financial results.
• The company relies on third parties to market, sell, distribute, and maintain its products.
• The company's supply chain could be negatively impacted by macroeconomic developments.
• The company's estimated total addressable market is subject to inherent challenges and uncertainties.

Future Outlook

Cerus expects full-year 2025 product revenue to be in the range of $194 million to $200 million, reflecting 8% to 11% growth from 2024, and anticipates improvements to GAAP net loss and maintaining positive non-GAAP adjusted EBITDA for the full-year 2025.

Management Comments

• INTERCEPT double-digit product revenue growth in 2024 reflects the continued momentum of our platelets business and rising clinical demand for our IFC product, underscoring the expanding impact of our pathogen inactivation technology in transfusion medicine, stated William Obi Greenman, Cerus president and chief executive officer.
• Beyond our top-line growth, we delivered robust financial results, narrowing our GAAP net loss and achieving our communicated target of positive non-GAAP adjusted EBITDA for 2024 key metrics we remain committed to improving.
• After achieving positive adjusted EBITDA in 2024 and projecting growth based on our 2025 product revenue guidance, we anticipate leveraging the inherent strengths of our business for continued financial improvement.
• With a multi-billion dollar total addressable market for existing approved products, enduring customer trust and a first-mover advantage, we believe we are setting new standards in blood safety and are well-positioned for continued success.

Industry Context

Cerus operates in the blood safety market, focusing on pathogen reduction technologies. The company's performance reflects the increasing importance of blood safety and the adoption of pathogen inactivation systems in transfusion medicine.

Comparison to Industry Standards

• Cerus's 15% product revenue growth is strong compared to the overall growth rate of the blood transfusion market.
• Companies like Haemonetics, which also operate in the blood management space, have shown similar trends in revenue growth driven by increased demand for blood products and related technologies.
• The achievement of positive adjusted EBITDA sets Cerus apart from some smaller biotech companies that are still focused on R&D and not yet profitable.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive outlook.
• Employees may benefit from the company's improved financial performance and growth prospects.
• Customers will continue to have access to the INTERCEPT Blood System for improved blood safety.
• Suppliers may see increased demand for their products as Cerus expands its operations.

Next Steps

• The company will host a conference call to discuss the financial results and provide a business overview and outlook.
• Cerus will continue to focus on commercializing the INTERCEPT Blood System and expanding its market presence.
• The company will continue to develop its pipeline programs, including the INTERCEPT Blood System for RBCs.

Key Dates

Keywords

Cerus Corporation, financial results, product revenue, INTERCEPT Blood System, EBITDA, blood safety, pathogen reduction, transfusion medicine